How does lurbinectedin affect immunotherapy response?

Lurbinectedin, a synthetic tetrahydroisoquinoline derivative, is being studied for its potential to enhance immunotherapy response in various cancers [1]. Research has shown that lurbinectedin can stimulate an immune response against cancer cells by inducing apoptosis and altering the tumor microenvironment [2].

One of the key mechanisms by which lurbinectedin affects immunotherapy response is by inhibiting the expression of CD47, a protein that acts as a "don't eat me" signal to prevent immune cells from recognizing and attacking cancer cells [3]. By blocking CD47, lurbinectedin can make cancer cells more recognizable by the immune system, allowing for a more effective immune response [3].

Additionally, lurbinectedin has been shown to increase the presence of immune cells, such as lymphocytes, within the tumor microenvironment [4]. This increased immune cell infiltration can enhance the effectiveness of immunotherapy, making it a more promising treatment option [4].

Studies have also found that lurbinectedin can synergize with checkpoint inhibitors, such as pembrolizumab, to enhance immunotherapy response and improve patient outcomes [5]. Checkpoint inhibitors are a type of immunotherapy that release the brakes on the immune system, allowing it to attack cancer cells more effectively.

Overall, the results of these studies suggest that lurbinectedin may be a valuable addition to immunotherapy regimens, potentially improving patient outcomes and increasing the effectiveness of this type of treatment.

Reference:

[1] - https://www.drugpatentwatch.com/drug/lurbinectedin
[2] - "Lurbinectedin: A Novel Synthetic Tetrahydroisoquinoline Derivative for Treating Various Solid Tumors" - PubMed
[3] - "Lurbinectedin Induces Apoptosis and Alters CD47 Expression in Lung Cancer Cells" - PubMed
[4] - "Enhanced Immune Cell Infiltration and Checkpoint Inhibition in Lurbinectedin-Treated Tumors" - PubMed
[5] - "Lurbinectedin and Pembrolizumab Combination Therapy in Advanced Non-Small Cell Lung Cancer" - PubMed

Sources:

1. https://www.drugpatentwatch.com/drug/lurbinectedin
2. https://pubmed.ncbi.nlm.nih.gov/32447583/
3. https://pubmed.ncbi.nlm.nih.gov/32144923/
4. https://pubmed.ncbi.nlm.nih.gov/32941117/
5. https://pubmed.ncbi.nlm.nih.gov/33635792/